Humacyte Stock Today

HUMAW Stock  USD 1.77  0.12  6.35%   

Performance

13 of 100

 
Weak
 
Strong
Good

Odds Of Distress

Over 69

 
High
 
Low
Quite High
Humacyte is selling for under 1.77 as of the 19th of June 2024; that is -6.35 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.77. Humacyte has more than 69 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Humacyte are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of March 2024 and ending today, the 19th of June 2024. Click here to learn more.

Moving together with Humacyte Stock

  0.75VAXX VaxxinityPairCorr

Moving against Humacyte Stock

  0.77DRMA Dermata TherapeuticsPairCorr
  0.69DOMH Dominari HoldingsPairCorr
  0.62CDIOW Cardio DiagnosticsPairCorr
  0.6EQ EquilliumPairCorr
  0.51VANI Vivani Medical Earnings Call Next WeekPairCorr
  0.49VERA Vera TherapeuticsPairCorr
Humacyte cannot be verified against its exchange. It appears that Humacyte is not available for investing at the moment. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Refresh

Humacyte Stock Highlights

Business ConcentrationPharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Humacyte (HUMAW) is traded on NASDAQ Exchange in USA. It is located in 2525 East North Carolina Highway 54, Durham, NC, United States, 27713 and employs 183 people. Humacyte is listed under Pharmaceutical Products category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry. Humacyte generates negative cash flow from operations
Check Humacyte Probability Of Bankruptcy

Humacyte Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Humacyte market risk premium is the additional return an investor will receive from holding Humacyte long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Humacyte. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Humacyte's alpha and beta are two of the key measurements used to evaluate Humacyte's performance over the market, the standard measures of volatility play an important role as well.

Humacyte Stock Against Markets

Try Other Suggestions

H Hyatt HotelsCompany
HBANM Huntington Bancshares IncorporatedCompany
HIE Millerhoward High IncomeFund
HF DGA Absolute ReturnETF
HGX PHLX HousingIndex
HT HTCryptocurrency
H3698DDR2 CS 6373 15 JUL 26Corporate Bond
HGUSD CopperCommodity

Humacyte Corporate Management

Harold AltersonSenior QualityProfile
MS MSChief OfficerProfile
Sabrina OsborneExecutive PeopleProfile
Kiernan MDChief OfficerProfile
Dale SanderChief CFOProfile
William ScheesseleChief OfficerProfile

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.